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ABSTRACT
Objective: The aim of this study was to determine whether and to what degree proton-pump inhibitor (PPI) use affects blood magnesium levels.
Methods: We performed a cross-sectional comparative study with consecutive sampling technique from June to October 2016. This study compared 
blood magnesium levels of patients using PPIs (lansoprazole and omeprazole) with those of patients not taking PPIs. The total sample was 184 patients. 
Data collected included questionnaires and medical records. Statistical analysis was performed with the unpaired t-test, Mann–Whitney U-test, and 
one-way analysis of variance.
Results: The average magnesium level in patients using PPIs was 2.08±0.21 mg/dL, whereas the average magnesium level in patients not using PPIs 
was 2.27±0.38 mg/dL, a statistically significant difference (p<0.001). Magnesium levels were significantly lower in patients using PPIs for >1 year 
and in patients using omeprazole (p<0.05).
Conclusion: Blood magnesium levels of patients using PPIs were significantly lower than those who did not use PPIs. Decreased levels of magnesium 
in patients using PPI are affected by PPI type and the duration of PPI use - >1 year. Thus, the long-term use of PPIs may lead to decreased levels of 
magnesium. Therefore, monitoring the levels of magnesium is important in patients using PPIs for a long term to avoid the risk of hypomagnesemia.
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INTRODUCTION
A recent review of the United States Federal Drug Administration 
(US FDA) adverse event reporting system from 2004 to 2009 
summarized 216 hypomagnesemia events related to omeprazole or 
esomeprazole use [1]. Consequently, the US FDA issued a warning 
in 2011, announcing that the long-term use of all proton-pump 
inhibitors (PPIs) could result in severe hypomagnesemia [2]. In several 
case reports and case series, it was already noted that PPI-induced 
hypomagnesemia primarily occurs in patients who use PPIs for a long 
period (i.e., ≥3 months) [3]. PPI-related hypomagnesemia was first 
reported by Epstein, McGrath, and Law in 2006 [4].
PPI-associated hypomagnesemia can cause a range of symptoms, 
including tremors of the extremities, convulsions (40%), muscle cramps 
and spasms (20%), weakness and lethargy (30%), tetany (17%), loss 
of consciousness, numbness, anxiety, hallucinations, agitation (20%), 
dizziness, and nausea (36%) [5].
PPIs are widely used by patients who receive antihypertensives, 
antidiabetics, analgesics, antibiotics, anticonvulsants, antiemetics, 
statins, and psychiatric drugs to suppress dyspepsia associated 
with the use of these drugs [6]. Some of the PPIs used in Indonesia 
are esomeprazole, omeprazole, lansoprazole, and pantoprazole. 
Omeprazole and lansoprazole are more often prescribed to patients 
because they are included in the national formulary. The purpose of 
this study was to determine whether and to what degree PPI use affects 
blood magnesium levels.
METHODS
We performed quantitative research using a cross-sectional comparative 
study. Approval was obtained from the Ethics Committee of the medical 
faculty of the University of Indonesia and the Research Department 
of Dr. Cipto Mangunkusumo National General Hospital. A comparative 
study was conducted on two populations: A group of patients using 
PPIs and another group of patients not using proton PPIs. The total 
sample in this study was 184 patients (92 in each group). We collected 
data using questionnaires and medical records. Statistical analysis was 
performed using the unpaired t-test and one-way analysis of variance 
(ANOVA). Patients who dropped out of the study were excluded from 
the study. Inclusion criteria were as follows: (a) Patients who used a PPI 
for 3 months or more and patients who use a PPI and had no history of 
PPI use and (b) patients who were willing to participate in this research.
RESULTS AND DISCUSSION
Comparison of blood magnesium levels between PPI users and 
non-users
Using an unpaired t-test, we found that the blood magnesium level in 
patients using PPIs was significantly lower than that in non-users. The 
mean blood magnesium levels in the patients are shown in Table 1.
Assessment of potential confounding variables contributing to 
patient blood magnesium levels
The majority of participants in both the groups were female and <60 years 
of age. Diuretics were the only other class of drugs used by the participants. 
The majority of patients in both the groups did not have diabetes mellitus 
(DM). Differences in the mean blood magnesium level based on gender, 
age, and DM status were not statistically significant by the Mann–Whitney 
U-test (Table 2). The results of the Mann–Whitney U-test for the use of 
diuretics indicated the meaningful differences between the mean blood 
magnesium levels in patients using diuretics (p=0.007).
Multivariate linear regression was conducted on the groups, and the use 
of diuretics along with the use of PPIs had the most influential effect on 
the decrease in blood magnesium levels (p<0.001). Multivariate linear 
regression results are shown in Table 3.
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Assessment of the relationship between dose and duration of PPI 
use with the patients’ blood magnesium levels
Omeprazole was the PPI most widely used by patients in this study 
(51.1%). The doses of PPIs that were the most widely used were 
omeprazole at 20 mg/day and lansoprazole at 30 mg/day (56%). The 
duration of PPI use in our study was ≥366 days in 62% PPI users and 
between 90 and 180 days in 14.1%. The results of an unpaired t-test 
conducted on the type and dose of PPI were not statistically significant. 
One-way ANOVA test results conducted on the duration of PPI use 
showed that there is a statistically significant difference in the blood 
magnesium levels between the two groups. The results of a post hoc 
analysis showed significant differences in the blood magnesium levels 
in the group of patients who used PPIs for 181–365 days and those who 
used them for 366 days or more. Test results for the effect of the type 
and duration of PPI use on blood magnesium levels are shown in Table 4.
Results of a multivariate linear regression test showed that the PPI type 
and duration of PPI use affect the blood magnesium levels. The results 
of this multivariate analysis are shown in Table 5.
DISCUSSION
Our cross-sectional comparative study showed that the blood magnesium 
levels of patients using PPIs significantly differed from those of patients 
who did not use PPIs. These results are similar to those of studies 
conducted by Shah and Sachdeva [6]. Our study involved 92 patients 
who were taking PPIs and 92 patients who did not use PPIs; only one 
patient using PPIs had hypomagnesemia. Patients taking PPIs and who 
have hypomagnesemia usually show no symptoms of hypomagnesemia 
(asymptomatic). This result correlates with that of Hess et al. [7], who 
reported that many cases of hypomagnesemia related to the use of 
PPIs are asymptomatic. According to Tamura et al., the symptoms of 
hypomagnesemia that results from the long-term use of PPIs would occur 
if the blood magnesium levels were <1.22 mg/dL [1]. The prevalence of 
hypomagnesemia related to the use of PPIs is not known exactly [8,9].
Our study compares the blood magnesium levels between patients 
taking omeprazole and those taking lansoprazole. The results showed 
no significant differences between the mean blood magnesium levels in 
patients taking omeprazole versus those taking lansoprazole. Similar 
results were reported by Gau et al. [10].
Our analysis showed significant differences in the blood magnesium levels 
in the group of patients who used PPIs for 181–365 days versus those 
who used PPIs for >366 days. This result correlates with the research by 
Kieboom et al., which states that the risk of hypomagnesemia increases 
when using PPIs for a long period (>6 months) [3]. Hess et al. suggested 
that the onset of hypomagnesemia resulting from the long-term use of 
PPIs varies from 14 days to 13 years (with an average of 5.5 years) [7].
Koulouridis et al. reported that hypomagnesemia associated with 
the long-term use of PPIs was not associated with the doses of PPIs 
used [11]. Our study results showed that there was no significant 
difference between the blood magnesium levels according to the dose 
of PPI used by the patient.
The results of this study showed no significant difference between 
males and females with respect to the blood magnesium levels. Takeda 
et al. also reported no significant difference in the blood magnesium 
levels between men and women [12]. Our results also showed no 
meaningful differences between the mean blood magnesium levels 
according to patient age, and similar results were reported by Lindner 
et al. in 2014 [13].
The use of loop diuretics and thiazide can stimulate the loss of 
magnesium in the kidney by decreasing the passive reabsorption of 
magnesium or indirectly interfere with magnesium homeostasis by 
inhibiting sodium reabsorption [7]. The US FDA states that the use of 
loop diuretics and thiazide can reduce the levels of magnesium whether 
used alone or in combination with other antihypertensives (angiotensin-
converting enzyme inhibitors, β-blockers, and/or angiotensin receptor 
blockers) [2]. The present study showed meaningful differences 
between the mean levels of magnesium in patients using diuretics. 
Studies conducted by Danziger et al. in patients with critical conditions 
who used a combination of drugs with PPIs and diuretics had a larger 
decrease in magnesium levels [14].
DM can decrease magnesium levels. Decreased magnesium levels in 
patients with diabetes may be caused by a lack of intake of foods high in 
magnesium, the high excretion of magnesium in the kidney, deficiency/
insulin resistance, decreased absorption of magnesium in the kidney, 
insensitivity to insulin that affects magnesium transport and glucose 
metabolism, metabolic acidosis (diabetic ketoacidosis), and the use of 
loop diuretics and thiazide [15-18]. The results of this study indicate 
that DM does not affect the levels of magnesium, which is similar to the 
results reported by Takeda et al. [12].
The limitations of our study are that we obtained blood magnesium 
level data at 1-time point (cross-sectional), and we did not analyze 
blood magnesium levels before and after the use of PPIs (cohort).
Magnesium absorption in the small intestine occurs by both active 
transport and passive absorption. Active transport mediated by the 
transport proteins such as transient receptor potential melastatin 
6 (TRPM6) and TRPM7 is responsible for 30% of the absorption 
process, whereas the passive transport through the tight junctions of 
enterocytes is responsible for 70% of the remaining absorption [19]. 
An in vitro study conducted by Thongon and Krishnamra showed that 
the transport of cations that pass through the cell lining of the large 
intestine is greatly reduced by treatment with PPIs [20].
Table 1: Mean blood magnesium levels based on PPI use
Group n Mean±SD (mg/dL) p-value
Patients using PPIs 92 2.08±0.21 0.000
Patients not using PPIs 92 2.27±0.38
Unpaired t-test, p<0.05=Significant. PPIs: Proton-pump inhibitors, SD: Standard 
deviation
Table 2: Mean blood magnesium levels based on gender, age, use 
of diuretics, and DM
Variable n Mean±SD (mg/dL) p-value
Gender
Male 76 2.17±0.31 0.645
Female 108 2.18±0.33
Age
≤60 years 129 2.17±0.28 0.714
>60 years 55 2.18±0.40
Use of Diuretic
Yes 8 1.93±0.17 0.007
No 176 2.19±0.3
DM
Yes 27 2.20±0.52 0.928
No 157 2.17±0.28
p<0.05=Significant. DM: Diabetes mellitus, SD: Standard deviation
Table 3: Results of multivariate linear regression of blood 
magnesium levels based on group and the use of diuretics
Step Variable Coefficient Coefficient 
correlation
p-value
Step 1 Group 0.167 0.259 0.000
Use of diuretics −0.166 −0.105 0.152
Constant 1.936 0.000
Step 2 Group 0.182 0.281 0.000
Constant 1.907 0.000
p<0.05=Significant
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Intracellular magnesium regulates TRPM6 activity according to pH, 
whereby a more acidic milieu increases TRPM6 activity [21,22]. 
Since PPI therapy decreases gastric hydrogen ion secretion, thereby 
increasing lumen pH, PPI use could potentially decrease TRPM6 activity, 
resulting in decreased magnesium absorption. Under the condition 
of magnesium deficiency, PPIs may inhibit magnesium absorption by 
increasing the pH of the intestinal lumen through both gastric and 
non-gastric antagonisms of the H+–K+ ATPase pump (proton pump). 
TRPM6/7 affinity for magnesium decreases in a higher pH environment. 
While this may trigger mRNA transcription of TRPM6 channels in most 
individuals, hypomagnesemia may develop when this compensation is 
incomplete or the individual has additional risk factors [23].
CONCLUSION
Blood magnesium levels of patients using PPIs were significantly 
lower than those in patients who did not use PPIs. Decreased levels 
of magnesium in patients using PPI are affected by PPI type and the 
duration of PPI use for >1 year. Thus, the long-term use of PPIs may lead 
to decreased levels of magnesium. Therefore, monitoring the levels of 
magnesium is important in patients using PPIs for a long term to avoid 
the risk of hypomagnesemia.
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Table 4: Mean blood magnesium levels based on the PPI type and dose and duration of use in patients using PPIs
Variable n Mean±SD (mg/dL) p-value
Type of PPI
Omeprazole 47 2.04±0.23 0.070
Lansoprazole 45 2.13±0.18
Dose of PPI
Omeprazole 20 mg/day; Lansoprazole 30 mg/day 56 2.10±0.2
0.342Omeprazole >20 mg/day; Lansoprazole >30 mg/day 36 2.06±0.2
Duration of PPI use (days)
90–180 13 2.13±0.25 0.020
181–365 22 2.18±0.19
≥366 57 2.04±0.20
Type and dose of PPI: Unpaired t-test: Duration use of PPI: One-way ANOVA test, p<0.05 was considered significant, post–hoc LSD test: 90–180 versus 181–365 days, 
p=0480, 90–180 versus ≥366 days, p=0158, 181–365 days ≥ versus 366 days, p=0.008. PPIs: Proton-pump inhibitors, SD: Standard deviation
Table 5: Results of multivariate linear regression of blood 
magnesium levels based on the PPI type and duration of PPI use 
in patients
Step Variable Coefficient Coefficient 
correlation
p-value
Step 1 Type of PPI 0.118 0.275 0.010
Duration use of PPI −0.090 −0.304 0.004
Constanta 2.135 0.000
p<0.05 = Significant, PPIs: Proton-pump inhibitors
